TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NervGen Pharma ( (TSE:NGEN) ) has provided an announcement.
NervGen Pharma announced expanded data from its CONNECT SCI Study, showcasing unprecedented improvements in function, independence, and quality of life for individuals with chronic spinal cord injury. The study highlights NVG-291’s potential as the first pharmacologic treatment for spinal cord injury, with significant functional gains and quality of life improvements observed in participants, marking a significant milestone for the company and offering hope for the SCI community.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic disorders.
YTD Price Performance: 20.48%
Average Trading Volume: 83,587
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$294.2M
For detailed information about NGEN stock, go to TipRanks’ Stock Analysis page.